[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351191-105":59,"doc-detail-351191-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-patient-derived-organ-on-chip-platform-for-modeling-the-tumor-microenvironment-and-drug-responses-in-pancreatic-cancer","A Patient-Derived Organ-on-Chip Platform for Modeling the Tumor Microenvironment and Drug Responses in Pancreatic Cancer","","Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy, and conventional chemotherapy is insufficient for effective control, driving demand for precision medicine. Ex vivo models that faithfully reproduce tumor biology and its microenvironment can support individualized therapy. This work develops a patient-derived platform that integrates PDOs with stromal and immune components (fibroblasts, endothelial cells, and immune cells) in a microfluidic organ-on-a-chip to model cancer-stroma crosstalk, evaluate standard chemotherapy, and assess immune checkpoint blockade effects on T cell cytotoxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-patient-derived-organ-on-chip-platform-for-modeling-the-tumor-microenvironment-and-drug-responses-in-pancreatic-cancer/351191/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-patient-derived-organ-on-chip-platform-for-modeling-the-tumor-microenvironment-and-drug-responses-in-pancreatic-cancer/351191.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are conventional chemotherapies inadequate for pancreatic ductal adenocarcinoma (PDAC)?","Question",{"text":112,"@type":113},"The document states that current conventional chemotherapeutics are inadequate to control the disease, creating urgent need for precision medicine.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the key limitation of patient-derived organoids (PDOs) for modeling PDAC?",{"text":117,"@type":113},"PDOs cannot fully replicate the tumor microenvironment, including key stromal and immune cells, and they lack vascularization/perfusion and dynamic fluid flow, limiting nutrient and waste exchange.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the proposed organ-on-a-chip (OoC) platform improve PDAC ex vivo modeling?",{"text":121,"@type":113},"It incorporates PDOs with critical TME components (fibroblasts, endothelial cells, and immune cells) in a microfluidic system, enabling modeling of cancer-stroma crosstalk and supporting evaluation of chemotherapy and immune checkpoint blockade responses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351191,1790195730,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Advanced Science    \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nA Patient-Derived Organ-on-Chip Platform for Modeling the Tumor Microenvironment and Drug Responses in Pancreatic Cancer  \nDarbaz Adnan1   Natan Roberto de Barros2  Luca S. Santovito3  Xuhong Cheng3  Kristi M. Lawrence1  Mariah K. Barnett1  Martine D. Boetto1  Neal Mehta4  Ajaypal Singh4  Lin Cheng5  Xiangsheng Huang3 Faraz Bishehsari1, 3, 6   \n1 Rush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, Illinois, USA  2National Laboratory of Bioscience (LNBio), National Center of Research in Energy and Materials (CNPEM), State of Sao Paulo, Brazil  3 Gastroenterology Research Center  \n(GRC)/Department of Internal Medicine, University of Texas Health Science Center At Houston, Houston, Texas, USA  4 Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA  5 Department of Pathology, Rush University Medical Center, Chicago, Illinois, USA  6MD Anderson  \nCancer Center, UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas, USA Correspondence: Faraz Bishehsari ([faraz.bishehsari@uth.tmc.edu](faraz.bishehsari@uth.tmc.edu))  \nReceived: 17 May 2025  Revised: 14 December 2025  Accepted: 15 December 2025  \nKeywords: microfluidic | organ on chip | pancreatic cancer | patient derived organoids | tumor microenvironment  \nABSTRACT  \nPancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy. Current conventional chemotherapeutics are inadequate in controlling the disease; hence, there is an urgent need for precision medicine. Ex vivo models that replicate the tumor and its microenvironment can advance precision medicine in PDAC. Patient-derived organoids (PDOs) offer a promising solution by retaining the functional features of the tumor, allowing for individualized study of cancer biology and drug response. However, PDOs fall short in replicating the tumor microenvironment (TME), which includes various stromal and immune cells influencing tumor growth and chemoresistance. We hypothesize that combining PDO technology with organ-on-a-chip (OoC) systems can enhance ex vivo cancer modeling. Here, we develop a patient-derived platform by incorporating PDOs with key components of the TME (fibroblasts, endothelial cells, and immune cells) within a microfluidic system. This OoC model represents the crosstalk between cancer and stroma observed in PDAC in vivo. Targeting the stroma improves the effectiveness of standard chemotherapy in this OoC. Further, using this platform, we are able to model and assess the efficacy of immune checkpoint blockade for T cell cytotoxicity in PDAC. The OoC provides a pathophysiologically applicable system to support future investigations aimed at utilizing precision medicine and testing therapeutics in PDAC.  \n1  Introduction  \nPancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy with poor survival outcomes, underscoring the inadequacy of conventional chemotherapy approaches [1] . The molecular heterogeneity of PDAC poses a significant challenge, contributing to inconsistent responses even to targeted therapies and underscoring the need for more personalized treatment approaches  \n[2–6] . These variations in response present substantial obstacles to trial designs for promising agents that pass animal testing [7–11] . PDAC is particularly challenging as it exhibits variable responses to therapy [12–18] .  \nIt is therefore important to establish efficient approaches for assessing the therapeutic potential of the current and future novel treatments [4, 19] . While animal models are costly, time-  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Advanced Science published by Wiley-VCH GmbH  \nAdvanced Science, 2026; 13:e08934 1 of 23  \n[https://d","cbCaikcfisgCdadu","https://ap.wps.com/l/cbCaikcfisgCdadu","pdf",8954989,23,"English","# Introduction\n## Patient-derived organoids and limitations\n## Organ-on-a-chip as an ex vivo modeling approach\n## Tumor microenvironment in PDAC","[{\"question\":\"Why are conventional chemotherapies inadequate for pancreatic ductal adenocarcinoma (PDAC)?\",\"answer\":\"The document states that current conventional chemotherapeutics are inadequate to control the disease, creating urgent need for precision medicine.\"},{\"question\":\"What is the key limitation of patient-derived organoids (PDOs) for modeling PDAC?\",\"answer\":\"PDOs cannot fully replicate the tumor microenvironment, including key stromal and immune cells, and they lack vascularization/perfusion and dynamic fluid flow, limiting nutrient and waste exchange.\"},{\"question\":\"How does the proposed organ-on-a-chip (OoC) platform improve PDAC ex vivo modeling?\",\"answer\":\"It incorporates PDOs with critical TME components (fibroblasts, endothelial cells, and immune cells) in a microfluidic system, enabling modeling of cancer-stroma crosstalk and supporting evaluation of chemotherapy and immune checkpoint blockade responses.\"}]","A Patient-Derived Organ-on-Chip Platform for Modeling the Tumor Microenvironment and Drug Responses in Pancreatic Cancer | PDF",1790093000,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/258ef2fd485afbf043110310ca04d4c9.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed12ffb0a6ae800c532799f843e045f5.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21716dd89ad7644fb1b2f2e2b9330fbc.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4048e665ceef3c5fa4fcd21ab1fcb7ae.webp",980,1287]